Education
About Us
Working with TipRanks
Follow Us
Sosei Group Corporation (JP:4565)
:4565
4565 Stock Chart & Stats
¥862.00
-¥10.00(-0.99%)
At close: 4:00 PM EST
¥862.00
-¥10.00(-0.99%)
Day’s Range― - ―
52-Week Range¥668.00 - ¥1,048.00
Previous CloseN/A
Volume458.60K
Average Volume (3M)945.56K
Market Cap
¥77.01B
Enterprise Value¥122.42B
Total Cash (Recent Filing)¥20.36B
Total Debt (Recent Filing)¥60.88B
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-85.49
Shares Outstanding90,496,735
10 Day Avg. Volume1,166,890
30 Day Avg. Volume945,556
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)80.32
Revenue Forecast (FY)¥43.00B
Bulls Say, Bears Say
Bulls Say
Commercial Product Momentum (PIVLAZ, QUVIVIQ)Sosei's marketed products now generate meaningful, growing revenue with PIVLAZ dominant in its Japan indication and QUVIVIQ rapidly expanding. A durable commercial foothold reduces reliance on one‑off deals, supports recurring cash flows, and anchors operational scaling and regional rollout over the next 2–6 months.
Commercial Unit Profitability And High Gross MarginsThe commercial unit's core profitability combined with sustained high gross margins indicates durable margin capture on product sales. This creates an internal cash‑generating engine that can fund pipeline investment and offsets platform cash burn, improving the company's structural earnings resilience if commercial trends persist.
Robust Discovery Platform And Advancing PipelineSosei Heptares' structure‑based GPCR discovery and multiple Phase II‑ready assets provide competitive differentiation and multiple value pathways: out‑license, milestone upside, and internal development. This structural R&D capability supports longer‑term dealflow and diversified future revenue beyond current commercial sales.
Bears Say
Widening Losses And Negative Free Cash FlowDespite revenue growth, escalating operating losses and sustained negative operating/free cash flow materially increase cash burn risk. Over several quarters this erodes liquidity cushions and forces reliance on external funding or deal monetization, constraining strategic optionality and elevating execution risk for profitability targets.
Higher Leverage Reduces Financial FlexibilityDebt near parity with equity weakens balance sheet resilience against ongoing losses. Higher leverage increases fixed obligations and limits capacity for opportunistic BD or clinical investments without additional financing, making sustained negative cash flow more consequential for long‑term strategy execution.
Revenue Lumpy And BD/milestone UncertaintyA meaningful share of revenue derives from partner milestones, which are inherently timing‑lumpy and unpredictable. The decline in milestone receipts highlights the risk that forecasted milestones or high‑value BD deals may not materialize on schedule, making revenue and cash generation less reliable and complicating plans to reach sustained profitability.
Sosei Group News
4565 FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was ¥668.00 and its highest was ¥1048.00 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is ¥77.01B.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is May 08, 2026 which is in 62 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on Feb 13, 2026. The company reported -¥85.49 earnings per share for the quarter, missing the consensus estimate of ¥73.9 by -¥159.39.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of ¥2.5 which represents an annual dividend yield of N/A. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 90,496,735 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of -¥85.49 in its last earnings report, missing expectations of ¥73.9. Following the earnings report the stock price went down -0.913%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in JP:4565
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Sosei Group Corporation (4565) is a biopharmaceutical company based in Japan, specializing in the discovery and development of innovative medicines. The company focuses on drug development in the fields of neurology, respiratory diseases, and oncology, leveraging its expertise in drug design and development to create novel therapies. Sosei Group operates through various subsidiaries and has a strong pipeline of product candidates that target significant unmet medical needs.
4565 Company Deck
4565 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: strong commercial execution in Japan/APAC and meaningful pipeline progress (Phase II–ready assets and partner-led late-stage programs) are clear positives, supported by rising product sales and a profitable commercial unit. However, FY2025 was marked by material operating losses, a notable decline in milestone revenue, higher R&D spend, and one-off charges. Management has announced restructuring, cost-reduction targets (>10%), and a plan to refocus the U.K. discovery portfolio, with expectations that benefits will appear in H2 FY2026. Given the balance between encouraging commercial/pipeline momentum and significant near-term financial and execution risks, the overall tone is cautious and transitional: opportunities exist but require successful execution of BD, cost actions, and regulatory steps to translate into the company’s stated FY2026 profitability goals.View all JP:4565 earnings summariesTechnical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
Options Prices
Currently, No data available
---